LOX-19260 is under clinical development by Loxo Oncology and currently in Phase III for Medullary Thyroid Cancer. According to GlobalData, Phase III drugs for Medullary Thyroid Cancer have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how LOX-19260’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LOX-19260 is under development for the treatment of medullary thyroid cancer and solid tumors. It acts by targeting proto-oncogene tyrosine protein kinase receptor Ret.
Loxo Oncology overview
Loxo Oncology a biopharmaceutical company that carries out the development of targeted small molecule therapeutics for the treatment of cancer. The company’s lead product includes IDH1/2 INHIBITOR, FGFR3 SELECTIVE, KRAS G12C INHIBITOR, Next-Gen RET INHIBITOR, PI3Ka INIBITOR and among others provides treatment for cancers. It also offers the ABEMACICLIB treats castrate-resistant prostate cancer, SELPERCATINIB 1L Medullary treats thyroid cancer, ABEMACICLIB treats hormone-sensitive prostate cancer. It is also developing a pipeline of additional product candidates targeting cancers driven by genetic alterations. Loxo Oncology is headquartered in Stamford, Connecticut, the US.
For a complete picture of LOX-19260’s drug-specific PTSR and LoA scores, buy the report here.